Premium
Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant
Author(s) -
Simioni Paolo,
Tormene Daniela,
Manfrin Davide,
Gavasso Sabrina,
Luni Sonia,
Stocco Domenico,
Girolami Antonio
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.01112.x
Subject(s) - asymptomatic , asymptomatic carrier , medicine , gastroenterology , thrombosis , prothrombin time
A recently discovered variant in the prothrombin gene (20210A) has been found in approximately 5–10% of patients with venous thromboembolism. It has been shown that patients with this variant present with high levels of prothrombin in plasma and this is maintained to be the most likely mechanism by which the risk of thrombosis is increased. We have evaluated prothrombin antigen levels in 50 carriers of the 20210A allele and compared with non‐carriers. 327 subjects were subdivided according to deficiency status and previous thrombosis. 30 symptomatic and 20 asymptomatic carriers had increased mean prothrombin levels as compared to symptomatic ( n = 178) or asymptomatic ( n = 99) non‐carriers. The percentage of subjects with prothrombin levels above cut‐off values of 1.15 u/ml or 1.30 u/ml was significantly higher in carriers of the prothrombin variant as compared to non‐carriers, regardless of a previous thrombosis. However, among non‐carriers the percentage of those with prothrombin levels above cut‐off values was significantly higher in the group of symptomatic as compared to asymptomatic individuals. In conclusion, increased prothrombin antigen levels, as detected by a specific ELISA, were found among 50 symptomatic and asymptomatic carriers of the 20210A prothrombin variant as well as among a large group of symptomatic non‐carriers. The data are in agreement with those found by using functional tests for the determination of prothrombin levels in these patients.